A clinical trial of Mecbotamab-vedotin in combination with Opdivo® (nivolumab)
Latest Information Update: 17 Jan 2022
At a glance
- Drugs Mecbotamab vedotin (Primary) ; Nivolumab (Primary)
- Indications Solid tumours
- Focus Therapeutic Use
- Sponsors BioAtla
Most Recent Events
- 17 Jan 2022 New trial record
- 10 Jan 2022 According to a BioAtla media release, company has entered into a clinical collaboration with Bristol Myers Squibb for this trial. BioAtla will serve as the study sponsor and will be responsible for costs associated with the trial execution. Bristol Myers Squibb will provide Opdivo clinical drug supply for the study.